Results 111 to 120 of about 274,562 (162)

Social Risk Factors and Disparities in Advanced Cardiovascular-Kidney-Metabolic Syndrome.

JAMA Netw Open
Ekwunife O, Wang X, Fraser RA, Yunke A, Campbell JA, Walker RJ, Egede LE.   +6 more
europepmc   +1 more source

The clinical importance of the cardiovascular-kidney-metabolic syndrome and related mortality. [PDF]

Front Clin Diabetes Healthc
Hoffmann K, Paczkowska A, Maggio V, Rizzo M.   +3 more
europepmc   +1 more source

Biomarkers for Screening and Diagnosis of Heart Failure in Cardiovascular-Kidney-Metabolic Syndrome: A Narrative Review. [PDF]

Int J Mol Sci
Pintea AM, Minciună IA, Pop D.
europepmc   +1 more source

Sex differences in the progression of cardiovascular-kidney-metabolic syndrome. [PDF]

Eur Heart J Open
Taya S, Ejiri K, Kaneko H, Suzuki Y, Miyoshi T, Mizuno A, Ko T, Jimba T, Azegami T, Okada A, Fujiu K, Takeda N, Morita H, Hayashi K, Node K, Nangaku M, Yasunaga H, Takeda N, Yuasa S.   +18 more
europepmc   +1 more source

Developmental origins and environmental determinants of cardiovascular-kidney-metabolic syndrome: A pediatric precision prevention perspective. [PDF]

Biomed J
Tain YL, Hsu CN.
europepmc   +1 more source

Correlation Between Dietary Index for Gut Microbiota With All-Cause and Cardiovascular Mortality in Cardiovascular-Kidney-Metabolic Syndrome Patients. [PDF]

Food Sci Nutr
Huang A, Hou L, Chen S, Lin B, Zhang Q.
europepmc   +1 more source

Implementing sodium-glucose co-transporter 2 inhibitors in cardiovascular-kidney-metabolic syndrome: a multidisciplinary expert perspective. [PDF]

Eur Heart J Cardiovasc Pharmacother
Avogaro A, Gori M, Grandaliano G, Iacoviello M, Trevisan R.   +4 more
europepmc   +1 more source

Reply: Metabolic Heterogeneity of Obesity and Outcome-Specific Effects of GLP-1 Receptor Agonists in Cardiovascular-Kidney-Metabolic Syndrome. [PDF]

JACC Adv
Kumar S, Anderson JE, Coviello A, Lopez-Jimenez F.   +3 more
europepmc   +1 more source

A novel mouse model for cardiovascular-kidney-metabolic syndrome: Bridging metabolic, renal and cardiac dysfunction. [PDF]

Mol Metab
van Koppen A, Inia JA, Gonzalez-Villalobos RA, Smits AM, Nawrocki AR, Hinke SA, Attema J, de Ruiter C, Nguyen TQ, Dendooven A, Bajema I, van Goor H, van Veen TAB, van Ham WB, Eichinger F, Elsborg SH, Mutsaers HAM, Pieterman EJ, Menke AL, Breyer MD, Stoop R.   +20 more
europepmc   +1 more source